BIOGEN, INC.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
AIDOC, INC.
DUKE UNIVERSITY
IQVIA HOLDINGS, INC.
AVALYN PHARMA INC.
REGENXBIO INC.
IRHYTHM TECHNOLOGIES, INC.
PONYA DIAGNOSTICS, LLC
MM
At a glance
Works on
Background
Career
DP
Washington, DC · current
Government experience
Counsel
Rep. Mollohan
Covered official positions, as disclosed on federal filings
The past 12 months
Clients
9
past 12 months
Filings
9
past 12 months
Agencies contacted
SENATEHOUSE OF REPRESENTATIVESCenters For Medicare and Medicaid Services (CMS)Executive Office of the President (EOP)Health & Human Services, Dept of (HHS)
Specific issues
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
National security issues related to pharmaceutical industry, including supply chain.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Trade policies and agreements, including IP protections, and administrative tariff actions.
Clients
Sources
This profile is built from the public record: filings in the U.S. Senate Lobbying Disclosure Act system. lda.senate.gov ↗